Vanguard Group Inc Avidity Biosciences, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 9,226,884 shares of RNA stock, worth $294 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
9,226,884
Previous 5,943,682
55.24%
Holding current value
$294 Million
Previous $243 Million
74.54%
% of portfolio
0.01%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding RNA
# of Institutions
255Shares Held
107MCall Options Held
224KPut Options Held
161K-
Price T Rowe Associates Inc Baltimore, MD10.6MShares$338 Million0.06% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$274 Million0.01% of portfolio
-
Rtw Investments, LP New York, NY8.13MShares$259 Million5.95% of portfolio
-
Wellington Management Group LLP Boston, MA7.03MShares$224 Million0.06% of portfolio
-
Avoro Capital Advisors LLC New York, NY6.88MShares$219 Million4.75% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $1.66B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...